Radiosurgery in Grade II and III Meningiomas: A Systematic Review and Meta-Analysis.

Background: Meningiomas are the most prevalent benign intracranial tumors. When they are of the invasive subtypes, i.e., grades II and III, they can recur rapidly and present a real challenge for physicians. This study is focused on the use of stereotactic radiosurgery to manage high-grade meningiomas.

Method: Medline via PubMed was searched from inception to December 2022 to retrieve studies on stereotactic radiation therapy for patients with grade II-III meningiomas. This study was conducted under PRISMA guidelines.

Result: A total of 29 articles involving 1446 patients with grade II-III meningiomas treated with stereotactic radiation therapy were included in the present study. Of these studies, 11 were conducted exclusively on patients with atypical meningiomas (grade II), 1 targeted anaplastic meningiomas (grade III), and 17 articles were carried out on both grade II and III meningiomas. The pooled 1, 2, 3, 5, and 10-year overall survival (OS) of grade II meningiomas was 0.96 [ < 0.01], 0.89 [ = 0.01], 0.90 [ = 0.09], 0.81 [ < 0.01], and 0.66 [ = 0.55], respectively. The pooled 2, 5, and 10-year OS of grade III meningiomas was 0.64 [ = 0.01], 0.41 [ = 0.01], and 0.19 [ < 0.01], respectively.

Conclusions: Although long-term prospective studies are still required, the outcomes of stereotactic radiation therapy appear promising regarding overall outcome and progression-free survival.